Objective: This study evaluated patterns of utilization and costs of percutaneous kidney biopsies in kidney transplant patients. Methods: The IBM Treatment Pathways tool was used to interrogate cohorts selected from the IBM MarketScan dataset. Analyses were done for both adult and pediatric patients. Differences in biopsy paid amounts and utilization patterns were assessed for commercial payers, Medicare, and Medicaid. Claims data were collected for the years 2016 to 2019. Results: A total of 15,337 records for percutaneous kidney biopsy events performed between 2016 and 2019 were identified in the database. Out of these, 840 corresponded to pediatric patients. Discussion: Analysis showed that the paid amount for the procedure increased by 10% from 2016 to 2019 for commercial payers for adult patients, with US $4,137 being the median paid amount in 2019. Median paid amounts by both Medicare and Medicaid remained essentially flat for the same time at US $2,063 for Medicare and US $865 for Medicaid in 2019. The median cost of the procedure in pediatric patients increased by 17% between 2016 and 2019 for commercial payers being US $6,068 in 2019. Medicaid payments for the pediatric patient population showed little change between 2016 and 2019, being US $1,666 in 2019.

The author received financial support from CareDx, Inc. for the research, writing, and publication of this article.

The author received financial support from CareDx, Inc. for the research, writing, and publication of this article.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors.